{"product_id":"abus-ansoff-analysis","title":"(ABUS) Arbutus Biopharma Corporation ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Ansoff Matrix Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Arbutus Biopharma Corporation Ansoff Matrix Analysis distills the company’s growth options—market penetration, market development, product development, and diversification—into a concise, actionable framework for strategy, investment, or planning. The page includes a real preview\/sample of the analysis so you can judge style and substance; purchase the full version to receive the complete, ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAB-729 Phase Ia\/Ib HBV positioning\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAB-729 is Company Name’s lead RNAi asset for chronic HBV, now in Phase Ia\/Ib and built to act in hepatocytes, the main HBV reservoir. This supports market penetration by deepening Company Name’s share in the existing HBV treatment-development space, where the unmet need is still high and long-term functional cure rates remain low. Phase I trials are the key gate before larger efficacy work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGalNAc subcutaneous delivery differentiation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAB-729’s subcutaneous dosing and covalent GalNAc targeting give Arbutus Biopharma Corporation a clearer, easier-to-use HBV profile than IV-only rivals. That matters in a market where WHO still estimates 254 million people live with chronic hepatitis B and 1.1 million new infections occurred in 2022. The delivery design supports penetration because it targets the same patient pool with a simpler administration path.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVaccitech triple-combination HBV study\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArbutus Biopharma Corporation’s clinical collaboration with Vaccitech plc tests AB-729 in a triple-combination regimen for chronic HBV, keeping it in the same market while widening treatment depth. Chronic hepatitis B still affects about 254 million people worldwide, so better combo data can support larger share capture. This is classic market penetration: same disease, stronger regimen, more patients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAB-836 oral capsid inhibition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAB-836 is Arbutus Biopharma Corporation’s oral capsid inhibitor, designed to suppress HBV DNA replication and widen its reach in chronic hepatitis B. With HBV still affecting about 254 million people worldwide and causing roughly 1.1 million deaths a year, a second clinical asset lets Arbutus push deeper into the treatment pathway and strengthen market presence.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOral capsid inhibitor for HBV DNA suppression\u003c\/li\u003e\n\u003cli\u003eAdds a second HBV mechanism\u003c\/li\u003e\n\u003cli\u003eExpands Arbutus Biopharma Corporation’s clinical footprint\u003c\/li\u003e\n\u003cli\u003eTargets a global HBV market of 254 million patients\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHBV antigen and replication reduction\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eArbutus Biopharma Corporation is pushing deeper into chronic HBV by aiming to cut HBV replication, HBsAg, and other viral antigens, which can raise treatment impact beyond simple suppression. AB-161 and AB-101 are meant to support RNA destabilization and immune re-engagement, fitting a market-penetration move in a chronic HBV pool that still includes about 254 million people worldwide.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets viral load and antigen reduction\u003c\/li\u003e\n\u003cli\u003eUses AB-161 and AB-101 to deepen response\u003c\/li\u003e\n\u003cli\u003eSupports stronger chronic HBV positioning\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArbutus Deepens Its HBV Market Penetration With AB-729 and AB-836\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eArbutus Biopharma Corporation’s market penetration move is to push deeper into chronic hepatitis B, not into a new disease area. AB-729, AB-836, and RNA-destabilizing programs target the same estimated 254 million people living with HBV worldwide, while WHO still counted about 1.1 million new infections in 2022 and 1.1 million deaths in 2022.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003ePenetration role\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAB-729\u003c\/td\u003e\n\u003ctd\u003eLead HBV RNAi asset\u003c\/td\u003e\n\u003ctd\u003ePhase Ia\/Ib\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAB-836\u003c\/td\u003e\n\u003ctd\u003eSecond HBV mechanism\u003c\/td\u003e\n\u003ctd\u003eOral capsid inhibitor\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHBV market\u003c\/td\u003e\n\u003ctd\u003eCore target pool\u003c\/td\u003e\n\u003ctd\u003e254 million patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Ansoff Matrix framework for analyzing Arbutus Biopharma Corporation’s growth strategy across products and markets\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a quick Arbutus Biopharma Ansoff Matrix snapshot to simplify growth strategy decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eConsolidates authoritative Arbutus sources to validate Ansoff Matrix growth paths, enabling fast verification and defensible strategy decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQilu China collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArbutus Biopharma Corporation's Qilu Pharmaceuticals Co., Ltd. link gives Arbutus a direct route into China, one of the world's largest chronic HBV markets; WHO estimates 254 million people lived with hepatitis B in 2022, with East Asia a key burden zone. This is clear geographic development, not just licensing. Qilu's China base helps Arbutus reach local patients, regulators, and hospitals faster.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartner-led international HBV reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArbutus Biopharma Corporation’s partner-led HBV reach scales market development through six named alliances: Alnylam Pharmaceuticals, Acuitas Therapeutics, Assembly Biosciences, Antios Therapeutics, Talon Therapeutics, and Gritstone Oncology. These deals spread research, licensing, and development risk beyond Arbutus’ base and widen access to global HBV programs. This model fits Ansoff market development: same science, broader partner channels.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical collaboration channel expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Vaccitech agreement gives Arbutus Biopharma Corporation an external clinical-development channel for AB-729, while the triple-combination study adds a new regimen setting inside chronic HBV. WHO estimates 254 million people live with chronic hepatitis B, so even small trial shifts matter. This expands where AB-729 can be tested and widens the partner-backed path to later-stage data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSubcutaneous HBV administration setting\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAB-729 is a subcutaneous HBV therapy, so market development is less about new chemistry and more about where it is given: hepatology clinics, specialty infusion sites, and other injectable-care settings. With chronic hepatitis B affecting about 296 million people worldwide, the addressable care pathway is large even before broad adoption. The subcutaneous route fits nurse-led dosing, monitoring, and repeat visits better than oral self-use.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInjectable specialty-care fit\u003c\/li\u003e\n\u003cli\u003eBroaden site-of-care access\u003c\/li\u003e\n\u003cli\u003eHBV burden: 296 million\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHBV portfolio across multiple partner networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eArbutus Biopharma Corporation is widening its HBV reach by running 4 mechanism tracks across partner networks: RNA interference, capsid inhibition, RNA destabilization, and PD-L1 inhibition. That multi-partner setup lowers single-asset risk and helps Arbutus plug into more HBV-focused development groups, which is a clear market development move in the Ansoff Matrix.\u003c\/p\u003e\n\u003cp\u003eIts HBV mix is built for combination use, not one-shot wins, so each program can fit a different collaborator path. The key edge is breadth: more mechanisms mean more shots at partnering, testing, and moving into HBV development chains.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e4 HBV mechanisms in play\u003c\/li\u003e\n\u003cli\u003eMultiple collaborator network fit\u003c\/li\u003e\n\u003cli\u003eBroader HBV partner access\u003c\/li\u003e\n\u003cli\u003eLower dependence on one asset\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArbutus Expands HBV Reach Through China Partner Qilu\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eArbutus Biopharma Corporation’s market development is mainly geographic and channel expansion for the same HBV assets, led by the Qilu Pharmaceuticals Co., Ltd. link into China. That matters because chronic hepatitis B still affects about 254 million people worldwide, with East Asia a major burden zone.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDriver\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina access\u003c\/td\u003e\n\u003ctd\u003eQilu route\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHBV burden\u003c\/td\u003e\n\u003ctd\u003e254 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner network\u003c\/td\u003e\n\u003ctd\u003e6 alliances\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoute\u003c\/td\u003e\n\u003ctd\u003eSubcutaneous HBV care\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eArbutus Biopharma Corporation Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAB-836 oral capsid inhibitor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAB-836 is an oral HBV capsid inhibitor designed to block HBV DNA replication, adding a new product layer to Arbutus Biopharma Corporation’s HBV franchise. Chronic hepatitis B still affects about 254 million people worldwide, so a better oral antiviral could widen the addressable market.\u003c\/p\u003e\n\u003cp\u003eThis fits product development in the Ansoff Matrix because it adds a new therapy class to an existing disease focus, rather than entering a new market. If AB-836 improves viral suppression versus older capsid inhibitors, it could strengthen Arbutus Biopharma Corporation’s HBV pipeline and partner value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAB-161 oral RNA destabilizer\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAB-161 is Arbutus Biopharma Corporation's oral HBV RNA destabilizer, designed to lower HBsAg and other viral proteins by breaking down HBV RNA. The program adds a distinct hepatitis B mechanism to the pipeline, giving Arbutus a broader shot at functional cure alongside other HBV assets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAB-101 oral PD-L1 inhibitor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAB-101 is Arbutus Biopharma Corporation’s oral PD-L1 inhibitor for chronic hepatitis B, designed to re-engage HBV-specific immune responses and add an immune-based option in the same HBV market. That fits product development: the company is extending its HBV franchise beyond antiviral work into immunotherapy, in a market with about 254 million people living with chronic hepatitis B worldwide. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAB-729 GalNAc RNAi candidate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAB-729 is Arbutus Biopharma Corporation’s subcutaneous GalNAc RNAi candidate for chronic HBV, built to enter hepatocytes and shut down viral replication plus multiple HBV antigens. In the Ansoff Matrix, it sits in product development: the Company is deepening its HBV franchise with a same-market, new-product asset.\u003c\/p\u003e\n\u003cp\u003eArbutus said in 2025 filings that AB-729 remains a core development program, alongside a cash position of about US$95 million at year-end 2024. That matters because HBV still affects about 254 million people worldwide, so even modest efficacy gains can support a large addressable market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCore chronic HBV asset\u003c\/li\u003e\n\u003cli\u003eSubcutaneous RNAi delivery\u003c\/li\u003e\n\u003cli\u003eTargets hepatocytes and antigens\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAB-729 plus Vaccitech regimen\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAB-729 plus the Vaccitech regimen moves Arbutus Biopharma Corporation from a single-agent HBV RNAi view to a triple-combination format. That is classic product expansion: HBV cure work often needs layered hits, since about 254 million people live with chronic hepatitis B worldwide.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTriple combo = broader product format\u003c\/li\u003e\n\u003cli\u003eFits HBV combination strategy\u003c\/li\u003e\n\u003cli\u003eTargets a large unmet market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArbutus Biopharma’s New HBV Drugs Target the Same Massive Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eArbutus Biopharma Corporation’s product development in the Ansoff Matrix centers on new HBV drugs for the same chronic hepatitis B market. AB-836, AB-161, AB-101, and AB-729 each add a new mechanism, while the HBV market still spans about 254 million people worldwide. Arbutus reported about US$95 million in cash at year-end 2024, supporting the pipeline.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eFit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAB-836\u003c\/td\u003e\n\u003ctd\u003eOral capsid inhibitor\u003c\/td\u003e\n\u003ctd\u003eNew product, same market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAB-161\u003c\/td\u003e\n\u003ctd\u003eOral RNA destabilizer\u003c\/td\u003e\n\u003ctd\u003eNew product, same market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAB-729\u003c\/td\u003e\n\u003ctd\u003eSubcutaneous RNAi\u003c\/td\u003e\n\u003ctd\u003eNew product, same market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSARS-CoV-2 small-molecule antivirals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArbutus Biopharma Corporation is diversifying into SARS-CoV-2 small-molecule antivirals, moving beyond its HBV core into a separate COVID-19 market. This is a true product-and-disease expansion, not just a line extension, and it targets a global pandemic with over 777 million reported cases and 7.1 million deaths worldwide.\u003c\/p\u003e\n\u003cp\u003eThe move widens Arbutus Biopharma Corporation’s addressable market and reduces HBV concentration risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOther coronavirus antiviral programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArbutus Biopharma Corporation’s other coronavirus antiviral programs widen its RNA and antiviral work from 1 virus to a broader coronavirus set, so this is clear diversification. That moves the Company into a new respiratory-virus market with new product candidates, not just hepatitis B. It also spreads scientific risk across more than 1 target and gives the platform a bigger addressable field.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-HBV antiviral discovery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArbutus Biopharma Corporation’s coronavirus work sits outside its HBV pipeline, so the company is not betting on one virus alone. Its antiviral discovery platform can move into a second therapeutic area, which expands the market beyond chronic HBV, a disease that affects about 296 million people worldwide. That diversification can reduce pipeline concentration risk and create more shots on goal.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCross-company research alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eArbutus Biopharma Corporation’s cross-company research alliances with Gritstone Oncology, Talon Therapeutics, Assembly Biosciences, Antios Therapeutics, Alnylam, Acuitas, and Qilu widen its R and D reach across seven partners and multiple scientific paths. That lowers single-program risk and spreads discovery cost across different commercial settings. One line: more partners can mean more shots on goal.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSeven named alliances\u003c\/li\u003e\n\u003cli\u003eBroader science base\u003c\/li\u003e\n\u003cli\u003eShared external R and D reach\u003c\/li\u003e\n\u003cli\u003eLess dependence on one program\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor Ansoff, this fits diversification because Arbutus is not relying only on one market or one asset class. The mix of biotech, delivery, oncology, and manufacturing partners supports optionality if one path stalls.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePlatform-based licensing model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eArbutus uses licensing and research collaborations to diversify beyond its core pipeline, since one deal can open adjacent nucleic-acid and liver disease targets without fully funding every program in-house. This platform-based model also spreads risk and can create milestone, royalty, and research income streams, which is valuable for a company with a small revenue base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpands into adjacent technologies.\u003c\/li\u003e\n\u003cli\u003eAdds non-dilutive funding paths.\u003c\/li\u003e\n\u003cli\u003eSupports partner-led market entry.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArbutus Expands Beyond HBV with Multiple Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eArbutus Biopharma Corporation’s diversification is still early but clear: it is moving from HBV into SARS-CoV-2 antivirals and broader coronavirus work, while using seven alliances to widen its science base and share risk. That gives the Company more shots on goal and less dependence on one disease area.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHBV core market\u003c\/td\u003e\n\u003ctd\u003e296 million people\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOVID-19 global cases\u003c\/td\u003e\n\u003ctd\u003e777 million+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOVID-19 global deaths\u003c\/td\u003e\n\u003ctd\u003e7.1 million+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNamed alliances\u003c\/td\u003e\n\u003ctd\u003e7\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234033148169,"sku":"abus-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/abus-ansoff-matrix.webp?v=1785709076","url":"https:\/\/dcfanalyst.com\/products\/abus-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}